5th Igenomix
APAC Symposium

Abstract

Japanese live birth is getting decreased, and experienced the lowest last year, 811,604, with a total fertility rate of 1.30. On the other hand, one out of 5.5 couples underwent fertility treatment as of 2015, and the ratio is getting increased. According to the latest report of the Japanese ART registry issued by Japan Society of Obstetrics and Gynecology (JSOG), 449,900 treatment cycles, including IVF, ICSI, and FET cycles, and 60,381 neonates were reported. The neonates born by ART technique account for one out of 13.9 babies born in 2020. As part of the policies to increase live births, the Japanese government started to apply health insurance for ART in April 2022, which was formerly covered by subsidy. In this lecture, I’ll share with you the policy change in ART in Japan. In addition, some changes in patients’ and cycles’ characteristics we have experienced at our ART clinic will be shown, although it is only 5 months since the application of insurance. Finally, I’ll discuss expected pros and cons of application of insurance, and future direction of ART in our country.

Biography

Miyuki Harada, M.D., Ph.D., is an Associate Professor of the Department of Obstetrics and Gynecology, Faculty of Medicine, at the University of Tokyo.

She is a board-certified specialist in Obstetrics/Gynecology, Reproductive Science, Women’s Health, and Laparoscopic Surgery. Dr. Harada received her degrees, M.D. and Ph.D., from the University of Tokyo. Her postdoctoral training included a fellowship at Prof. KMJ Menon Lab in ObGyn/Biochemistry, Medical School, at University of Michigan in Ann Arbor, USA.

Her research goal is to overcome ovarian dysfunction caused by various environmental and/or chronological insults and to provide preconception care targeting ovarian function. Her research has focused on follicular microenvironment regulating ovarian pathophysiology including PCOS, chemotoxicity, and ovarian aging. Recently, she has also been interested in gut microbiome in these pathologies. She has published 147 articles in leading medical journals, as of Aug 2022.

She is a member of ART registry subcommittee in the Ethics Committee of the Japan Society of Obstetrics and Gynecology (JSOG). She is currently working on the revision of the Guidelines for Reproductive Medicine in Japan.

Awards

1. Best Abstract Award by the Japanese Society of Anti-Aging Medicine (2020)
2. Rhoto Research Award on Women’s Health and Science (2020)
3. Society Encouragement Award by the Japan Society for Menopause and Women’s Health (2018)
4. International Session Award by the Japan Society of Obstetrics and Gynecology (2010)
5. Excellent Abstract Award by the Japan Society of Reproductive Medicine (2005)

Publications

1. Endoplasmic reticulum stress: a key regulator of the follicular microenvironment in the ovary. Mol Hum Reprod. 2021;27:gaaa088.
2. Fertility preservation for female cancer patients. Int J Clin Oncol. 2019;24:28-33.
3. Guidelines for Reproductive Medicine in Japan. Reprod Med Biol. 2022;21:e12483.
4. Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 1. Int J Clin Oncol. 2022;27:265-280.
5. Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2. Int J Clin Oncol. 2022;27:281-300.

Abstract

TBC

Biography

TBC

Awards

TBC

Publications

TBC

Abstract

TBC

Biography

Professor Thornhill received his PhD in Genetics (University of London) in 1996. Following post-doctoral work in single-cell genetics at the Institute of Child Health, Alan trained as a clinical embryologist before directing IVF laboratories in the USA and UK specializing in Preimplantation Genetics and is currently registered as a clinical scientist by the UK’s Health and Care Professions Council.

Alan is honorary Professor in Reproductive Genetics at the University of Kent, was formerly Deputy Chair of the ESHRE PGD Consortium, Chair of Alpha, Scientists in Reproductive Medicine and a Professional Member of the UK’s fertility regulator, the HFEA.

Alan moved to the biotech industry in 2013 as Associate Director, Market Development for Illumina’s fertility business in EMEA.

Since 2017, he has been Igenomix UK’s Country Manager and Senior Scientific Advisor. Alan’s research interests include reproductive genetics, PGD and improving IVF safety and effectiveness.

With over 70 peer-reviewed articles and book chapters, Alan is a passionate communicator and enjoys speaking regularly to schools, lay audiences, national and international conferences.

Awards / Publications

TBC